Global Macular Edema and Macular Degeneration Market Trends 2025–2029: Regional Outlook and Sizing Analysis
Claim your 20% discount on Global Market Reports with code ONLINE20. Limited time only.
What Is The Projected Valuation Of The Macular Edema and Macular Degeneration Market In The Coming Years?
Over the past several years, the market size for macular edema and macular degeneration has seen significant growth. It is projected to rise from $9.65 billion in 2024 to $10.33 billion in 2025, boasting a compound annual growth rate (CAGR) of 7.0%. Factors contributing to the growth during this historical period include an aging population, increasing diabetes prevalence, improved awareness and early detection, global eye health movements, innovations in pharmaceuticals, and patient advocacy and support.
In the near future, robust expansion is expected in the macular edema and macular degeneration market, with an anticipated worth of $13.44 billion in 2029, growing at a compound annual growth rate (CAGR) of 6.8%. This growth in the projected period can be credited to personalized medical strategies, increased awareness in burgeoning markets, emphasis on combination therapies, the inclusion of teleophthalmology services, and worldwide aging demographics. Key trends in the forecast span include progress in persistent drug delivery, the inclusion of gene therapies, the creation of innovative imaging technologies, custom treatment strategies based on biomarkers, the use of teleophthalmology for distant supervision and strides in artificial intelligence for diagnostics.
Get A Free Sample Of The Report:
https://www.thebusinessresearchcompany.com/sample.aspx?id=13479&type=smp
Which Growth Drivers Are Shaping The Macular Edema and Macular Degeneration Market Outlook?
The increasing cases of diabetes are projected to fuel the expansion of the macular edema and macular degeneration market in the future. Diabetes, a long-term health issue characterized by elevated blood sugar levels, impairs eye’s blood vessels, leading to conditions like macular edema and macular degeneration. For example, in June 2024, The National Health Service (NHS England), a publicly funded healthcare system based in the UK, reported an 18% rise in individuals identified as pre-diabetic from 3,065,825 in 2022 to 3,615,330 in 2023. Moreover, there was a significant increase of nearly 25% in cases among those below 40, escalating from 173,166 in 2022 to 216,440 in 2023. Thus, the escalating prevalence of diabetes is contributing to the growth of the macular edema and macular degeneration market.
What Is The Segment Breakdown Of The Macular Edema and Macular Degeneration Market?
The macular edema and macular degenerationmarket covered in this report is segmented –
1) By Treatment Type: Drug Therapy; Laser Treatment
2) By Application: Macular Edema; Diabetic Macular Edema (DME); Cystoid Macular Edema (CME); Macular Degeneration; Dry age-related macular degeneration; Wet age-related macular degeneration
3) By End User: Hospitals; Clinics; Other End Users
Subsegments:
1) By Drug Therapy: Anti-VEGF (Vascular Endothelial Growth Factor) Injections; Steroid Injections; Oral Medications; Combination Therapy (Anti-VEGF + Steroids)
2) By Laser Treatment: Focal Laser Photocoagulation; Panretinal Photocoagulation (PRP); Subthreshold Laser Therapy; MicroPulse Laser Therapy
How Are Global Trends Impacting The Development Of The Macular Edema and Macular Degeneration Market?
Primary players in the macular edema and macular degeneration industry are aiming to enhance their market profitability by introducing inventive products like Vabysmo (faricimab-svoa). This medicine caters to conditions such as neovascular age-related macular degeneration (nAMD) and diabetic macular edema (DME). For instance, Genentech Inc., an American biotech company, received the Food and Drug Administration’s approval for Vabysmo (faricimab-svoa) in January 2022. It’s a bispecific antibody that targets vascular endothelial growth factor (VEGF) and angiopoietin 2 (Ang-2) and is the first bispecific monoclonal antibody produced for these two conditions. The drug faricimab holds the promise to become a game-changing medication for handling nAMD and DME, and its acceptance by FDA and EU has marked a significant achievement for Genentech and Roche.
Who Are The Major Stakeholders Operating In The Macular Edema and Macular Degeneration Market?
Major companies operating in the macular edema and macular degeneration market report are F. Hoffmann La Roche Ltd., AbbVie Inc., Bayer AG, Novartis AG, GlaxoSmithKline PLC, Amgen Inc., Regeneron Pharmaceuticals Inc., Biogen Inc., Bausch Health Companies Inc., Clover Therapeutics Inc., Santen Pharmaceutical Co. Ltd., Samsung Bioepis Inc., PanOptica Inc., Regen X Bio Inc., Aerie Pharmaceutical Inc., Apellis Pharmaceuticals Inc., Kubota Pharmaceutical Holdings Co. Ltd., Alimera Sciences Inc., Kodiak Sciences Inc., Acucela Inc., Editas Medicine Inc., IVERIC bio Inc., Lineage Cell Therapeutics Inc., Allegro Ophthalmic Ltd., Ampio Pharmaceuticals Inc., Neurotech Pharmaceuticals Inc., Graybug Vision Inc., Clearside Biomedical Inc., Ocugen Inc., Opthea Limited
Access The Complete Report Here:
Which Region Is Likely To Register The Fastest Growth In The Macular Edema and Macular Degeneration Market?
North America was the largest region in the macular edema and macular degeneration market in 2024. The regions covered in the macular edema and macular degeneration market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Customize Your Report Here:
https://www.thebusinessresearchcompany.com/customise?id=13479&type=smp
Browse Through More Reports Similar to the Global Macular Edema and Macular Degeneration Market 2025, By The Business Research Company
Age Related Macular Degeneration Global Market Report 2025
Macular Degeneration Treatment Global Market Report 2025
Alopecia Global Market Report 2025
https://www.thebusinessresearchcompany.com/report/alopecia-global-market-report
About The Business Research Company:
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Asia +44 7882 955267 & +91 8897263534
Europe +44 7882 955267
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
